14-9943-85

antibody from Invitrogen Antibodies

Targeting: TGFB1 CED, DPD1, TGFB, TGFbeta

ELISA (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

14-9943-85

Provider

Invitrogen Antibodies

Product name

TGF beta-1,2,3 Monoclonal Antibody (eBioTB2F), eBioscience™

Antibody type

Monoclonal

Antigen

Other

Description

Description: The eBioTB2F antibody reacts with Transforming Growth Factor-beta (TGF-beta), a pleiotropic cytokine, exists in five isoforms, known as TGF-beta1-5. Homologies between isoforms range from 70-80% but no homology exists to TGF-alpha. TGF-beta1 is ubiquitous and the most abundant form found in lymphoid organs, while other isoforms are expressed in a more restricted distribution. The biologically active state of all isoforms are disulfide-linked homodimers. The heat- and acid- stable monomeric subunits have a length of 112 amino acids. The isoforms of TGF-beta arise by proteolytic cleavage of longer precursors; the isoforms are derived from the carboxyterminal ends of these precursors. Isoforms isolated from different species are evolutionarily closely conserved and have sequence identities on the order of 98%. Mature human, porcine, simian, chicken and bovine TGF-beta1 are identical and differ from mouse TGF-beta1 in a single amino acid. TGF-beta1 is produced in very high levels by platelets. Other cellular sources of TGF-beta1 include macrophages, lymphocytes, endothelial cells, chondrocytes, and leukemic cells. TGF-beta1 secretion can be induced by steroids, retinoids, EGF, NGF, vitamin D3, and IL-1. Activities of TGF-beta1 include inhibition of cell growth for inhibitor for normal and transformed epithelial cells, endothelial cells, fibroblasts, neurons, and lymphoid cells and other hematopoietic cell types. TGF-beta1 inhibits the proliferation of T cells and NK cells and down regulates the activities of activated macrophages. TGF-beta1 blocks the anti-tumor activity of IL-2 - bearing lymphokine-activated killer (LAK) cells.

Antibody clone number

eBioTB2F

Concentration

0.5 mg/mL

References

Submitted references

Angiotensin-converting enzyme inhibitor works as a scar formation inhibitor by down-regulating Smad and TGF-β-activated kinase 1 (TAK1) pathways in mice.

Tan WQ, Fang QQ, Shen XZ, Giani JF, Zhao TV, Shi P, Zhang LY, Khan Z, Li Y, Li L, Xu JH, Bernstein EA, Bernstein KE
British journal of pharmacology 2018 Nov;175(22):4239-4252

---

NK-associated regulatory receptors in a structured HAART interruption of HIV-1-positive individuals.

Luque J, Lozano JM, García-Jurado G, Soriano-Sarabia N, González R, Vallejo A, Leal M, Peña J
AIDS research and human retroviruses 2008 Aug;24(8):1037-42

ELISA

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Standard curve of Anti-Human TGF beta ELISA. Recombinant cytokine standard concentration in pg/mL.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

2 ACEI reduces scar formation and TGF-beta1 expression on postoperative day 14. (A, B) Typical histological sections of mouse scar tissue obtained on the 14th postoperative day (A: HE staining, B: Masson staining). The green bars (A) are used to mark the scales of scar, the white bars = 500 mum (A) /100 mum (B). In each composite picture, K represents KO group, R represents ramipril group, L represents losartan group, H represents hydralazine group and B represents blank control group. (C) The actual (real) scar area and width were determined in each group of mice ( n = 12 wounds in six mice for each group). The results are given as mean +- SEM. * P < 0.05 as compared to the blank group respectively, by least significant difference (LSD) and Student-Newman-Keuls (SNK) tests (D) The content of TGF-beta1 in 1 g of scar tissue ( n = 12 wounds in six mice for each group). All results are given as mean +- SEM. * P < 0.05 as compared to the blank group, respectively, by LSD and SNK tests.